ALK and non-small cell lung carcinoma: For instance, the ALK G1128A mutation was detected via NGS in the ctDNA of an ALK-positive (ALK+) NSCLC patient who experienced disease progression after a brief partial response to crizotinib, highlighting the utility of liquid biopsy in identifying resistance mechanisms [84].